HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Plans Offices In China As Heparin Case Unfolds, With India On Deck

This article was originally published in The Tan Sheet

Executive Summary

FDA is moving rapidly to establish offices in Asia, with firm plans developing in China, and India next in line

You may also be interested in...

FDA kicks off “new era” in China

Health and Human Services Secretary Mike Leavitt opens FDA offices in China at the U.S. Embassy in Beijing, the U.S. Consulate General in Guangzhou and the U.S. consular mission in Shanghai, HHS says Nov. 18. "We're opening up a new era, not just new offices," Leavitt says, adding that eight senior agency officials in China will "ensure that quality and safety are built into food and consumer products at the point of manufacture." The U.S.-China partnership stems from a 2007 memorandum of agreement (1"The Tan Sheet" March 24, 2008, p. 16). HHS says FDA will have a presence in the Middle East, India, Europe and Latin America

FDA Strengthens Inspections Of Chinese Drug Firms In Heparin Aftermath

BEIJING - As FDA leaders select inspectors to deploy across three offices being set up in China, the agency is also preparing to ramp up the number of inspections and the level of scrutiny of Chinese drug manufacturers that export to the U.S

Import Alert On Drugs From Ranbaxy’s Plants Includes OTC Product

India's largest drug maker, Ranbaxy, faces a hurdle to growing its U.S. business with FDA's ban on imports of some of its products, including an OTC drug

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts